D9268C00001

Research code: D9268C00001
Research name: Open randomised phase III research evaluating Dato-DXd (datopotamab derukstekan) compared with investigator-selected chemotherapy in patients with inoperable or disseminated breast cancer without HER2 receptor overexpression and with estrogen and/or progesterone receptors who have previously received systemic treatment with one or two lines of chemotherapy (TROPION-Breast01).
Indication: breast cancer
Principal researcher: Ewa Chmielowska, MD, PhD
Research population: patients with luminal B-cell carcinoma
Investigated drug: datopotamab deruxtecan